In his new role, Manku, a member of the editorial board since 2004, vows to maintain the journal's unusual aim of distributing novel, radical ideas in medicine and related biomedical sciences while employing a more traditional peer review process than the journal saw under its previous editor,Bruce Charlton,whose contract was terminated after he refused to implement such a system.
"First, we will retain the ethos, heritage and unique characteristics of the journal as they were proposed at inception," Manku said in a statement. "Second, we will engage a medically qualified editorial board to get members more involved in the review system to help ensure radical new ideas and speculations in medicine are given open-minded consideration while ensuring scientific merit."
He may have a long road ahead of him -- last month, editorial board member William Bainsspoke withThe Scientistand said most of the board planned to resign in response to Elsevier's changes to the journal, which found itself in hot water after Charlton chose to publish an article by notorious AIDS denialist Peter Duesburg of the University of California, Berkeley. Duesburg was subsequently the subject of a university investigation launched last November to determine whether he had violated the university's code of conduct by submitting the article toMedical Hypotheses, but was cleared of the charges earlier this week.
Manku is executive editor and editor-in-chief of a leading journal in the lipid field,Prostaglandins, Leukotrienes and Essential Fatty Acids, and part-time chief scientist at Amarin Corporation, a biopharmaceutical company focused on cardiovascular disease.
Elsevier Announces New Medical Hypotheses Editor-in-Chief